

Leif Stenke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10030218/publications.pdf>

Version: 2024-02-01

68
papers

1,895
citations

393982

19
h-index

264894

42
g-index

68
all docs

68
docs citations

68
times ranked

2882
citing authors

#	ARTICLE	IF	CITATIONS
1	Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study. <i>American Journal of Hematology</i> , 2022, 97, 421-430.	2.0	7
2	The acute radiation syndrome—need for updated medical guidelines. <i>Journal of Radiological Protection</i> , 2022, 42, 014004.	0.6	7
3	Mental health and psychosocial consequences linked to radiation emergencies—increasingly recognised concerns. <i>Journal of Radiological Protection</i> , 2022, 42, 031001.	0.6	2
4	Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI. <i>Leukemia</i> , 2021, 35, 2416-2418.	3.3	13
5	Successful tyrosine kinase inhibitor discontinuation outside clinical trials—data from the population-based Swedish chronic myeloid leukaemia registry. <i>British Journal of Haematology</i> , 2021, 193, 915-921.	1.2	9
6	Long-term tolerability and efficacy after initial PegIFN- α 1 addition to dasatinib in CML—CP: Five-year follow-up of the NordCML007 study. <i>European Journal of Haematology</i> , 2021, 107, 617-623.	1.1	4
7	Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorogenic effects on CML cells. <i>Cell Death and Disease</i> , 2021, 12, 875.	2.7	6
8	Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results. <i>Blood</i> , 2021, 138, 635-635.	0.6	2
9	Overall Survival and Adverse Events in 378 Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia - a Swedish Register-Based Nationwide Study. <i>Blood</i> , 2021, 138, 3750-3750.	0.6	1
10	Increased Risk of Chronic Myeloid Leukemia Following Gastric Conditions Indicating Helicobacter pylori Infection: A Case-Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 151-156.	1.1	3
11	Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia. <i>JACC: CardioOncology</i> , 2020, 2, 123-126.	1.7	6
12	Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. <i>Oncology</i> , 2019, 8, e1638210.	2.1	19
13	Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 555-567.	1.0	4
14	Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. <i>Bone Marrow Transplantation</i> , 2019, 54, 1764-1774.	1.3	33
15	Interferon β is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cells. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 502-508.	1.0	11
16	Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. <i>Blood</i> , 2017, 129, 2384-2394.	0.6	113
17	Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. <i>Haematologica</i> , 2017, 102, 1361-1367.	1.7	28
18	Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38+ stem and progenitor cells in chronic myeloid leukemia. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 378-384.	1.0	11

#	ARTICLE	IF	CITATIONS
19	Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1543-1554.	1.2	20
20	The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia. <i>European Journal of Haematology</i> , 2017, 98, 398-406.	1.1	14
21	Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era – a report from the Swedish CML register. <i>European Journal of Haematology</i> , 2017, 98, 57-66.	1.1	13
22	Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia. <i>PLoS ONE</i> , 2017, 12, e0171041.	1.1	7
23	Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence. <i>European Journal of Haematology</i> , 2016, 97, 387-392.	1.1	31
24	Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. <i>Annals of Internal Medicine</i> , 2016, 165, 161.	2.0	86
25	Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 4030-4038.	3.2	20
26	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 612-621.	5.1	214
27	The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1181-1191.	1.9	71
28	Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. <i>British Journal of Haematology</i> , 2015, 169, 683-688.	1.2	49
29	Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 559-564.	2.0	58
30	Mature, Adaptive-like CD56DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission. <i>Blood</i> , 2015, 126, 343-343.	0.6	3
31	Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study. <i>Blood</i> , 2015, 126, 4022-4022.	0.6	0
32	Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?. <i>Journal of Clinical Oncology</i> , 2014, 32, 2821-2823.	0.8	122
33	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. <i>Cancer Cell</i> , 2014, 26, 428-442.	7.7	292
34	Increased Risk of Cardiovascular Events Associated with TKI Treatment in Chronic Phase Chronic Myeloid Leukemia. Data from Swedish Population-Based Registries. <i>Blood</i> , 2014, 124, 3134-3134.	0.6	6
35	Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). <i>Blood</i> , 2014, 124, 519-519.	0.6	30
36	Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells. <i>Blood</i> , 2014, 124, 812-812.	0.6	33

#	ARTICLE	IF	CITATIONS
37	Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. <i>Blood</i> , 2013, 122, 1284-1292.	0.6	110
38	Gene Expression Analyses At Time Of Diagnosis Indicate Biomarkers Predictive Of Therapeutic Response In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2619-2619.	0.6	1
39	Disease Relapse After TKI Discontinuation In CML Is Related Both To Low Number and Impaired Function Of NK-Cells:Data From Euro-SKI. <i>Blood</i> , 2013, 122, 379-379.	0.6	12
40	Dasatinib Treatment Induces Fast and Deep Responses In Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients In Chronic Phase: Clinical Results From a Randomized Phase 2 Study (NordCML006). <i>Blood</i> , 2013, 122, 4032-4032.	0.6	4
41	Early PK-Analysis Predicts Molecular Response In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib. <i>Blood</i> , 2013, 122, 1485-1485.	0.6	0
42	Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib. <i>Blood</i> , 2013, 122, 2731-2731.	0.6	0
43	Leukemic Stem Cell Quantification Is Of Prognostic Value In Newly Diagnosed Patients In Chronic Phase Chronic Myeloid Leukemia (CML-CP) Receiving Nilotinib Therapy: Results From The ENEST1st Stem Cell Substudy. <i>Blood</i> , 2013, 122, 649-649.	0.6	0
44	First Global Consensus for Evidence-Based Management of the Hematopoietic Syndrome Resulting From Exposure to Ionizing Radiation. <i>Disaster Medicine and Public Health Preparedness</i> , 2011, 5, 202-212.	0.7	91
45	Literature Review and Global Consensus on Management of Acute Radiation Syndrome Affecting Nonhematopoietic Organ Systems. <i>Disaster Medicine and Public Health Preparedness</i> , 2011, 5, 183-201.	0.7	78
46	Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18-60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG. <i>Blood</i> , 2011, 118, 2520-2520.	0.6	2
47	Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38 ⁺ Stem Cell Level: Results From Randomized NordCML006 Study. <i>Blood</i> , 2011, 118, 784-784.	0.6	2
48	Landmark Analysis of Imatinib Treatment in CML Chronic Phase: ES-FISH <10% Ph+ At 3 Months Associated with Better Cytogenetic Response and Improved Long-Term Event-Free Survival. <i>Blood</i> , 2011, 118, 1702-1702.	0.6	0
49	Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd. <i>Blood</i> , 2010, 116, 2291-2291.	0.6	12
50	Individualized Multidrug Resistance In Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 2491-2491.	0.6	0
51	The Proportion of Ph+ CD34+CD38 ^{neg} Leukemic Stem Cells in the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI-Therapy. Data From a Randomized Phase II NordCML006 Study. <i>Blood</i> , 2010, 116, 667-667.	0.6	0
52	Large Granular Lymphocyte (LGL) Expansions Comprising Oligoclonal T Cell or NK Cell Populations in Dasatinib Treated Patients Are Associated with HLA-A*0201, CMV Reactivation and Enhanced Anti-Leukemic Control.. <i>Blood</i> , 2009, 114, 1123-1123.	0.6	17
53	Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 790-790.	0.6	124
54	Landmark Analyses of BCR-ABL Using ES-FISH Early After Start of Imatinib Treatment to Newly Diagnosed CMLcp Patients Predicts Longterm Clinical Outcome.. <i>Blood</i> , 2009, 114, 4269-4269.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Mono/Oligoclonal T and NK Cells Are Common in Philadelphia Chromosome Positive (Ph+) Leukemia Patients at Diagnosis and Expand During Successful Tyrosine Kinase Inhibitor Therapy.. Blood, 2009, 114, 856-856.	0.6	1
56	Gene Array Biomarkers in Acute Myeloid Leukemia to Predict Remission Duration.. Blood, 2009, 114, 3466-3466.	0.6	0
57	Analysis of γ H2AX and NHEJ Signaling as Molecular Determinants for GOSensitivity in AML. Blood, 2008, 112, 4854-4854.	0.6	0
58	The Importance of CD33 Expression and Pro-Apoptotic Signalling for Gemtuzumab Ozogamicin-Induced Cytotoxic Effects on AML Cells. Blood, 2008, 112, 5041-5041.	0.6	0
59	Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy. Blood, 2008, 112, 573-573.	0.6	3
60	Clonal Large Granular Lymphocyte (LGL) Expansion Associated with Dasatinib Therapy.. Blood, 2007, 110, 2938-2938.	0.6	4
61	Global Proteomics in AML: Using SELDI-TOF MS on Diagnostic Samples To Identify Spectra and Protein Biomarkers Indicative of Prognosis.. Blood, 2006, 108, 4436-4436.	0.6	0
62	Detection of Proteins Related to Therapeutic Outcome, Including Drug Resistance, in Acute Myeloid Leukemia Using Mass Spectrometry and Gel Based Proteomic Profiling.. Blood, 2005, 106, 2367-2367.	0.6	0
63	Gemtuzumab Ozogamicin Combined with Hyper-CVAD in Relapsed Refractory CD33-Positive Acute Lymphoblastic Leukemia.. Blood, 2005, 106, 4572-4572.	0.6	0
64	Novel enzymatic abnormalities in AML and CML in blast crisis: elevated leucocyte leukotriene C4synthase activity paralleled by deficient leukotriene biosynthesis from endogenous substrate. British Journal of Haematology, 1998, 101, 728-736.	1.2	14
65	Expression of mRNA encoding neurotrophins and neurotrophin receptors in human granulocytes and bone marrow cellsâ€”enhanced neurotrophin-4 expression induced by LTB4. Journal of Leukocyte Biology, 1998, 64, 228-234.	1.5	33
66	Elevated white blood cell synthesis of leukotriene C4in chronic myelogenous leukaemia but not in polycythaemia vera. British Journal of Haematology, 1990, 74, 257-263.	1.2	32
67	The tyrosine kinase inhibitor nilotinib targets discoidin domain receptor 2 in calcific aortic valve stenosis.. British Journal of Pharmacology, 0, , .	2.7	5
68	To be (prepared) or not to be â€” that is hardly the question.. Journal of Radiological Protection, 0, , .	0.6	2